NeoGenomics Launches PanTracer Pro to Expedite Solid Tumor Therapy Decisions
NeoGenomics launched PanTracer Pro on February 12, 2026 to support timely, informed selection of solid tumor therapies. The platform is designed to integrate comprehensive molecular profiling results into clinical decision workflows within oncology treatment centers.
1. PanTracer Pro Launch
NeoGenomics introduced PanTracer Pro on February 12, 2026, unveiling a new diagnostic platform aimed at accelerating and improving solid tumor therapy decisions. The system integrates detailed molecular profiling into clinical workflows, enabling oncology teams to access treatment-relevant data more quickly and personalize therapy regimens based on comprehensive genomic insights.
Related News
JEPI
Active ETFs Shift Holdings Daily, Provide Downside Protection, Charge 0.4%-1% Fees
JEPI•
AAPL
Apple App Store Blocks 1 Billion Fake Accounts, Prevents $2.2B Fraud
AAPL•
NVDA
Nvidia Projects $20 Billion in CPU Sales Within $200 Billion Market
NVDA•
PERI
Perion Q1 Revenue Rises 1% as Outmax AI Spend Soars 300% and CTV Spend Jumps 68%
PERI•
NVDL
GraniteShares 2x Daily Nvidia ETF Gains 172%, Tops $4 Billion AUM
NVDL•
Sources
B